One of a handful of gene therapy companies with pipelines that include Pompe disease. Today AVROBIO announced a halt to their programs.
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
Amicus Therapeutics, announces the approval of Opfolda (miglustat) capsules, an enzyme stabilizer of cipaglucosidase alfa, by the European Commission for the treatment of Pompe disease.
Pompe Day is wrapping up soon for another year. It’s important to point out that for Pompe families, Pompe Day is 365 days long.
We still live in a world where there are over 300 million people living with over 6,000 rare diseases. That’s enough to populate the 3rd largest country in the world. We have the tools to diagnose them quicker, but we aren’t doing it.
Recently, preclinical data were presented at the 18th Annual WORLDSymposium in San Diego, CA, supporting MZE001 as a treatment for Pompe disease.
Starting Jan 16, 2022, this online series brings together Pompe disease families and other experts in five 2-hr sessions over 11 days.
Health Canada has approved avalglucosidase alfa (Nexviazyme™) for the long-term treatment of late-onset Pompe disease in patients over the age of 6 months.
In a recent announcement, the Pompe disease community learned that the U.S. Food and Drug Administration (FDA) has approved Nexviazyme® for the treatment of late-onset Pompe patients that are one year old and older.
Amicus Therapeutics recently announced topline results of its phase 3 PROPEL study of its combination therapy, AT-GAA, for the treatment of late onset Pompe disease (LOPD).
The Spark Therapeutics phase 1/2 gene therapy trial testing SPK-3006 to treat late onset Pompe disease has officially started with the first person being given their first (and theoretically only) dose.